Lingxu Jiang

#79 Qingchun Road
Hangzhou, 310003, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms.

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms.

Journal: Blood cancer journal

Published: February 04, 2026

EZH2 inhibition induces pyroptosis via RHA-mediated S100A9 overexpression in myelodysplastic syndromes.

EZH2 inhibition induces pyroptosis via RHA-mediated S100A9 overexpression in myelodysplastic syndromes.

Journal: Experimental hematology & oncology

Published: October 25, 2024

The molecular prognostic scoring system for normal karyotype myelodysplastic syndromes.

The molecular prognostic scoring system for normal karyotype myelodysplastic syndromes.

Journal: Journal of translational medicine

Published: October 19, 2024

Moderate-To-Severe Bone Marrow Fibrosis Is an Independent Risk Factor For Myelodysplastic Neoplasms Patients With Increased Blasts.

Moderate-To-Severe Bone Marrow Fibrosis Is an Independent Risk Factor For Myelodysplastic Neoplasms Patients With Increased Blasts.

Journal: Hematological oncology

Published: July 25, 2024

RIPK3 deficiency blocks R-2-hydroxyglutarate-induced necroptosis in IDH-mutated AML cells.

RIPK3 deficiency blocks R-2-hydroxyglutarate-induced necroptosis in IDH-mutated AML cells.

Journal: Science advances

Published: April 17, 2024

The m6A methyltransferase METTL14 promotes cell proliferation via SETBP1-mediated activation of PI3K-AKT signaling pathway in myelodysplastic neoplasms.

The m6A methyltransferase METTL14 promotes cell proliferation via SETBP1-mediated activation of PI3K-AKT signaling pathway in myelodysplastic neoplasms.

Journal: Leukemia

Published: October 07, 2023

Mutation landscape of normal karyotype myelodysplastic syndromes and their prognostic impact.

Mutation landscape of normal karyotype myelodysplastic syndromes and their prognostic impact.

Journal: American journal of hematology

Published: September 20, 2023

Serial monitoring of circulating tumour DNA on clinical outcome in myelodysplastic syndromes and acute myeloid leukaemia.

Serial monitoring of circulating tumour DNA on clinical outcome in myelodysplastic syndromes and acute myeloid leukaemia.

Journal: Clinical and translational medicine

Published: June 20, 2023

15-days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high-risk myelodysplastic syndromes: A retrospective single-center study.

15-days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high-risk myelodysplastic syndromes: A retrospective single-center study.

Journal: Hematological oncology

Published: March 24, 2022

All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex.

All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex.

Journal: British journal of cancer

Published: February 26, 2022

Predictive values of mutational variant allele frequency in overall survival and leukemic progression of myelodysplastic syndromes.

Predictive values of mutational variant allele frequency in overall survival and leukemic progression of myelodysplastic syndromes.

Journal: Journal of cancer research and clinical oncology

Published: June 08, 2021

Real-world data of chronic myelomonocytic leukemia: A chinese single-center retrospective study.

Real-world data of chronic myelomonocytic leukemia: A chinese single-center retrospective study.

Journal: Cancer medicine

Published: October 15, 2020

Showing 1-12 of 17

Last Updated: 09/26/2026